Our research programs in hemophilia A and B may be the first major advances in hemophilia treatment in more than a decade. Currently in phase III development, our long-lasting recombinant clotting factors may have the potential to require less frequent infusions, improve compliance and reduce the burden of chronic treatment. To differentiate our products and create a competitive advantage, we will address the unmet needs of patients with hemophilia and their physicians, leverage our strength in delivering patient services and build on our manufacturing expertise.
Ongoing phase III clinical trials of our factor VIII and factor IX product candidates will have important data readouts in 2012. Meanwhile, we continue to put commercial infrastructure in place, develop relationships with the medical and scientific community and build a suite of patient services to create the optimal patient experience.